phase ii trial
Recently Published Documents


TOTAL DOCUMENTS

9299
(FIVE YEARS 1263)

H-INDEX

139
(FIVE YEARS 18)

2022 ◽  
Vol 162 ◽  
pp. 161-169
Author(s):  
Sophie Cousin ◽  
Coralie Cantarel ◽  
Jean-Philippe Guegan ◽  
Thibault Mazard ◽  
Carlos Gomez-Roca ◽  
...  

Author(s):  
Maureen M. O'Brien ◽  
Lingyun Ji ◽  
Nirali N. Shah ◽  
Susan R. Rheingold ◽  
Deepa Bhojwani ◽  
...  

PURPOSE Children's Oncology Group trial AALL1621 was conducted to prospectively determine the safety and efficacy of inotuzumab ozogamicin (InO) in pediatric and adolescent patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). PATIENTS AND METHODS This single-arm phase II trial enrolled patients age 1-21 years with R/R CD22-positive B-ALL. In cycle 1, InO dosing was 0.8 mg/m2 intravenously on day 1 and 0.5 mg/m2 on days 8 and 15 of a 28-day cycle with response evaluation at day 28. Using a two-stage design, the trial was continuously monitored for dose-limiting toxicities and sinusoidal obstruction syndrome (SOS). CD22 expression was retrospectively evaluated by central flow cytometry. RESULTS Forty-eight patients were evaluable for response and toxicity; 19 had complete response (CR) and nine CR with incomplete count recovery (CRi) after cycle 1 (CR/CRi rate: 58.3%; two-sided 90% CI, 46.5 to 69.3). Twenty-seven of 28 patients with CR or CRi had minimal residual disease measured by flow cytometry; 18 (66.7%) had minimal residual disease < 0.01%. Seven of 28 patients (25%) with CR or CRi had delayed count recovery past day 42 in cycle 1. Three (6.3%) patients had grade 3 ALT elevation and one patient had grade 3 hyperbilirubinemia in cycle 1. Of 21 patients undergoing hematopoietic stem-cell transplantation after InO, 6 (28.6%) developed grade 3 SOS. Partial CD22 expression and lower CD22 site density were associated with lower likelihood of response to InO. CONCLUSION InO is effective and well tolerated in heavily pretreated children and adolescents with R/R CD22-positive B-ALL. SOS after hematopoietic stem-cell transplantation and prolonged cytopenias were notable. CD22 modulation was identified as a mechanism of resistance. Expanded study of InO combined with chemotherapy is underway.


Author(s):  
Raquibul Hannan ◽  
Michael Christensen ◽  
Hans Hammers ◽  
Alana Christie ◽  
Brendan Paulman ◽  
...  

2022 ◽  
Vol 43 ◽  
pp. 101224
Author(s):  
Ronald B. Turner ◽  
Liisa Lehtoranta ◽  
Ashley Hibberd ◽  
Sofia Männikkö ◽  
Bryan Zabel ◽  
...  

2021 ◽  
Vol 131 (24) ◽  
Author(s):  
Mark Yarchoan ◽  
Leslie Cope ◽  
Amanda N. Ruggieri ◽  
Robert A. Anders ◽  
Anne M. Noonan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document